Title of Invention

A DEVICE FOR DETECTION OF ANTIBODIES TO HIV AND p24 ANTIGEN OF HIV 1 IN HUMAN SERUM OR PLASMA

Abstract The present invention HIV Ag & Ab Comb is a test device for the early detection of p24 antigen and HIV1 and HIV 2 antibodies in human serum or plasma or whole blood. It is a visual, rapid, sensitive and accurate test kit for analyzing the presence of HIV antibodies and he workability of the device can be tested simultaneously with the detection of the presence of p24 antigen and antibodies to HIV.
Full Text

The present invention relates to the device for the determination of the HIV in human
serum / plasma/ whole blood.
More specifically the present invention relates to the process for making the HIV Comb
for the early detection of HIV1 and HIV 2 antibodies and HIV p 24 antigen in human
serum or plasma or whole blood.
The present invention relates to detection kit for the early detection of the presence of
HIV 1 and HIV 2 antibodies and p24 antigen in human serum or plasma or whole blood.
HIV Comb+ Ag is a visual and rapid, sensitive and accurate test device for analyzing the
presence of HIV 1 and HIV 2 antibodies and HIV p 24 antigen in human serum or plasma
or whole blood.
It is a test device wherein the presence of antibodies to HIV1, HIV2 and p24 antigen and
workability of the test device is determined separately and simultaneously.
Moreover the early detection is extremely important for all the patients regardless of
lifestyle in reducing the further transmission.
Back ground
HIV stands for Human Immunodeficiency Virus. HIV is the virus that causes AIDS. Its
transfusion is resulting from blood transfusion. AIDS disease, which is primarily caused
by infection of individuals with a HIV retrovirus, is now the most devastating disease in
the whole world, since the number of individuals which are, to date, infected with HIV
viruses is estimated to about 40 millions of individuals.
During the year 2001, 5 millions of individuals were infected with HIV while 3 millions
of individuals have deceased in the same time. Since the discovery of the main AIDS
causative agent in 1983, namely the HIV virus, extensive efforts have been made in order
to understand the mechanism of action of this virus and to develop accurate methods for
2

(i) reproducibly diagnosing the infection, as well as (ii) carrying out a prognosis of the
progression of the disease in a given patient.
There are two kinds of viruses, HIV 1 and HIV 2 which causes the infection. These two
viruses are retroviruses group and are slow viruses. This knowledge has laid a foundation
for the development of a new assay based on the Recombinant DNA technology leading
to the differential detection of antibodies to HIV-1 and HIV-2 in human serum or plasma.
Prior Arts
US Patent No: 6870045: describes the kit for detecting HIV-2. It describes the
compositions and method for synthesizing and detecting HIV-2 specific amplicons.
Particularly described are oligonucleotides that are useful as hybridization probes, and
amplification primers that facilitate detection of very low levels of HIV-2 nucleic acids.
US Patent No. 20060257318 describes the field of diagnosis of the progression status of
an infection of an individual with a virus belonging to the family of HIV as well as with
the therapeutical treatment of this infection disease.
US Patent No.20060234209: describes the microchip based assays to measure HIV
associated analysts of interest in a sample from a subject infected with the HIV virus.
Methods of present invention are optimal for use in monitoring HIV disease in resource
poor settings.
US Patent No: 7115363: The invention relates to a new class of retroviruses, designated
by HIV-2, of which samples have been deposited to the ECACC under numbers
87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates
to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and
gpl40. These various antigens can be used for the diagnosis of the disease, especially by
contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to
immunogenic compositions containing more particularly the glycoprotein gpl40. Finally
it concerns nucleotidic sequences, which can be used especially as hybridization probes,
derived from the RNA of HIV-2.
3

US Patent No: 7083922: relates to oligonucleotides for use in amplifying and detecting
HIV nucleic acid in a sample.
Description
HIV p24 antigen test device for the detection of the specific p24 antigen is a test device
for the early and rapid detection of the HIV in human serum or plasma. Antigen can
generally only be detected during the acute and during the symptomatic phase of AIDS.
Antibodies to HIV can be detected throughout virtually the entire infection period.
When the HIV virus enters into the body, the earlier detection of the disease is impossible
because the virus enters in window phase and subsequently the immune system start
producing antibodies. So the use of highly sensitive antibody assay is therefore an
established approach in serodiagnosis of HIV infection. Progressive improvements in
assay sensitivity have reduced that window phase. Further shortening of the period can be
achieved by the incorporation of HIV antigen detection in such antibody tests enabling
the detection of the infected individuals at the earliest possible moment. P24 detection
dot detects the specific p24 antigen of HIV. So early detection of HIV is possible.
The present invention relates to a test device for the earlier detection of p24 antigen and
antibodies to HIV1 & 2. It comprises of a comb, which is made of polystyrene plastic
sheet. The plastic was die-cut into "combs" having eight individual "teeth," each a
separate test, spaced to fit into a standard 96-well micro test plate in which an assay is
performed. It has three dots on the side of the each tooth, of which the upper dot is an
inbuilt control dot, which determines the process done is perfectly right. The central dot
is the dot for the determination of the p24 antigen and the lowest dot is for the
determination of the HIV-1 or HIV -2 antibodies. These three antigen and antibody dots
are immobilized as circular coats on the comb. The present invention relates to a rapid,
visual, sensitive and qualitative in vitro diagnostic kit for the detection of the HIV 1 and
HIV 2 antibodies and p24 antigens of HIV in human serum and plasma and whole blood
comprising a test polystyrene comb, wash buffer solution, sample diluent and conjugates.
4

There are five formats by which the test can be performed. Interpretations of results for
the five formats are same as described below.
On performing the test, if only the control dot appears which is pink in colour, then the
result is interpreted as negative and the procedure carried out for the detection are
perfectly right. If both the control dot and HIV-1 and HIV-2 antibody detection dot
appears in pink colour, then the result is that the patient's sample is reactive for HIV
antibody. If the control dot and p24 antigen detection dot appear in pink colour, then the
patient's sample is reactive for HIV p24 antigens. If the control dot, HIV p24 detection
dot and the HIV antibody dot appear pink in colour, then the patient's sample is reactive
for HIV antibody and p24 antigen.
The control dot to test the workability of the device is coated with antihuman IgG for eg.
rabbit, goat, donkey or chicken. HIV1 and HIV2 detection dot is coated with a mixture
of glycoprotein gp41, C terminus of glycoprotein gpl20 and glycoprotein gp36 which
is immobilized on the comb in the form of dot. p24 dot for the detection of p24 antigen is
coated with specific monoclonal or polyclonal or F(ab1)2 p24 antibodies. The quantity
used for the coating is 1 nanogram to 10 microgram for each protein.
Sample
The sample should be only human serum or plasma/ whole blood.
Principle
HIV-1 and HIV-2 antigens and p24 antibodies are immobilized on the polystyrene comb.
When the patient's sample is added to the device, HIV antibodies and p24 antigens if
present, bind to the coated antigens and p24 antibodies respectively. P24 antibody
conjugate is added which binds to the p24 antibody- antigen complex and protein A
conjugate binds to the Fc portion of HIV antibodies to give pinkish purple dots against
white background.
5

In an embodiment of the present invention, the process for making the HIV Ag & Ab
comb for analyzing the presence of HIV antibodies and p24 antigen in human serum or
plasma is as follows:
Preparation of HIV1 and HIV2 detection dot
To 5 mM - 100 mM carbonate buffer solution of pH 8- 9.6, add 1 nano gram to 10 micro
gram of each glycoprotein gp 41, C terminus of glycoprotein 120 and glycoprotein 36
and vortex the mixture to get a homogeneous solution. Coat 1 Μ1 — 10 μl of the above
mixture to the HIV 1 and HIV 2 detection dot and allow it to dry at 37 ° C for 1 to 20 hrs
and preferably 4 hrs.
Preparation of Control Dot
To 5 mM -100 mM carbonate buffer solution of pH 8- 9.6, add 1 nano gram to 10 micro
gram antihuman IgG for eg. of chicken or goat and vortex the mixture to get a
homogeneous solution. Coat 1 ΜL — 10 ul of the above mixture to the control dot and
allow it to dry at 37 ° C for 1 to 20 hrs and preferably 4 hrs.
Preparation of p24 detection dot
To 5 mM - 100 mM carbonate buffer solution of pH 8- 9.6, add 1 nano gram to 10 micro
gram specific monoclonal or polyclonal or F(ab )2 p24 antibodies and vortex the mixture
to get a homogeneous solution. Coat 1 ul - 10 ul of the above mixture to the p24 antigen
detection dot and allow it to dry at 37 ° C.
In an embodiment of the present invention, preparation of sample diluent is as follows.
To 10-100 mM Phosphate Buffer Saline of pH 7-8 , add detergent 0.01 % - 0.5% and
dye.
In an another embodiment the wash buffer solution is prepared by adding 50- 500 mM
Phosphate Buffer Solution of pH 6.5 - 8.5 to the detergent of 0.005 % - 0.5 % .
6

Example; 1
Preparation of protein A conjugate
1. To an initial solution of 0.01 % - 0.05% (w/v) Gold Chloride (HAuCl4) that is at
boiling temperature, sodium citrate solution (1-5%) is added . The solution is
rapidly stirred and boiled until a pink purple colour develops. Protein A is added
to the same.
2. Any non- immune animal serum (mouse / goat / rabbit /sheep) is added to the
above solution.
The concentration of serum could be lμg to 10μg /ml of gold colloid solution.
This solution is mixed for 2 hr to over night. After this the solution is centrifuged
and the supernatant is discarded. Dissolve the pellet in buffer containing
stabilizers such as BSA, Gelatin to obtain the Protein A conjugate.
Preparation of P24 conjugate.
1. To an initial solution of 0.01 % - 0.05% (w/v) Gold Chloride (HAuCl4) that is
at a boiling temperature, sodium citrate solution (1-5%) is added . The solution is
rapidly stirred and boiled until a pink purple colour develops. P24 antibody
monoclonal / polyclonal is added to the same. Adjust the pH of the gold Colloid
to 0.3 units higher than pI of p24 antibody monoclonal or poly clonal.
2. Any non- immune animal serum (mouse / goat / rabbit /sheep) is added to the
above solution.
The concentration of serum be 1μg tol0μg /ml of gold colloid solution. This
solution is mixed from 2 hrs to overnight. After this the solution is centrifuged
and the supernatant is discarded. Dissolve the pellet in buffer containing
stabilizers such as BSA, Gelatin to obtain the P24 conjugate. P 24 conjugate is in
lyophilized or liquid state.
7

Example 2;
Preparation of HIV 1 and HIV 2 conjugate.
1. To an initial solution of 0.01 % - 0.05% (w/v) Gold Chloride (HAucl4) that is at
a boiling temperature, sodium citrate solution (1-5%) is added . The solution is
rapidly stirred and boiled until a pink purple colour develops. Adjust the pH of the
Gold Chloride equal to 0.3 units higher than pi of Ag. Recombinant/ synthetic
peptides for HIV 1 and HIV2 is added to the same and mixed for 30 minutes to
1 hour . IgG from the species corresponding to the control dot is added and mixed
for one hour.
2. Any non- immune animal serum (mouse or goat or rabbit sheep) is added to the
above solution.
The concentration of serum could be lug tol0μg /ml of gold colloid solution.
This solution is mixed for 2 hrs to overnight. After this the solution is centrifuged
and the supernatant is discarded. Dissolve the pellet in buffer containing
stabilizers such as BSA, Gelatin to obtain the HIV 1 & 2 conjugate.
HIV 1 and HIV2 Conjugate is in lyophilized or liquid state.
Example 3:
Monoclonal or Polyclonal antihuman IgG gold conjugate
1. To an initial solution of 0.01 % - 0.05% (w/v) gold choride ( HAuC14) that is at
boiling temperature, sodium citrate solution (1-5%) is added. The solution is rapidly
stirred and boiled until a pink purple colour develops. Adjust the pH of the gold colloid
solution to 0.3 units higher than the PI of antibody. Monoclonal or Polyclonal antihuman
IgG is added to the same.
1. Any non - immune animal serum ( mouse/ goat/ rabbit/ sheep) is added to the
above solution. The concentration of the serum could be 1 ul to 10|al/ml of gold
colloid solution. This solution is mixed for 2 hr to overnight. After this the
8

solution is centrifuged and supernatant is discarded. Dissolve the pellet in buffer
containing stabilizers such as BSA, Gelatin to obtain the antihuman IgG Gold
conjugate.
In another embodiment of the present invention, test procedure for analyzing the presence
of HIV antibodies and p24 antigen in human serum and plasma is as follows:
1. Taking 150 μl of sample in the microcuvettes and add 150μl of sample diluent to
it.
2. Mixing the sample with the sample diluent repeatedly. Make sure that no bubbles
are formed while mixing the sample.
3. Cutting the pouch and take out the necessary no of combs and place it into the
microcuvettes-containing sample and incubate for 10 minutes at room
temperature. During incubation withdrawing and inserting the comb in the
microcuvettes for 15 seconds.
4. Removing the comb from the sample and blot the surface of the comb.
5. Washing the comb in the wash buffer solution for 10 times carefully by moving
the comb forward and back ward in the wash solution.
6. Placing the comb in the microcuvettes containing p24 conjugate and incubating it
for 10 minutes. Withdrawing and inserting the comb in the solution for 15
seconds
7. Washing the comb in the wash buffer solution.
8. Immersing the comb in to the microcuvettes containing protein A conjugate and
incubating for 10 minutes in room temperature. Withdrawing and inserting the
comb in to the microcuvettes containing protein A conjugate for 15 seconds.
9. Taking the comb out and placing the comb on a clean surface, reactive side up
and allowing it to dry.
10. Reading the result only after the comb is completely dry.
9

Example 4
Preparation of Streptavidin Gold conjugate.
1. To an initial solution of 0.01 % - 0.05% (w/v) Gold Chloride (HAuCl4) that is at a
boiling temperature, sodium citrate solution (1-5%) is added . The solution is
rapidly stirred and boiled until a pink purple colour develops. Streptavidin is
added to the same.
2. Any non- immune animal serum (mouse / goat / rabbit /sheep) is added to the
above solution.
The concentration of serum could be lμg tol0μg /ml of gold colloid solution.
This solution is mixed for 2 hrs to overnight. After this the solution is centrifuged
and the supernatant is discarded. Dissolve the pellet in buffer containing
stabilizers such as BSA, Gelatin to obtain the Streptavidin gold conjugate.
Biotinvlated solution of HIV 1. HIV2 and p24
Biotinylated solution of HIV1, HFV2 antigen and p24 antibody can be prepared
using commercially available biotinylant kit.
Test procedure
1. Taking 150 ul of sample in the microcuvettes and add 150μl of sample diluent to
it.
2. Mixing the sample with the sample diluent repeatedly. Make sure that no bubbles
are formed while mixing the sample.
3. Cutting the pouch and taking out the necessary no of combs and place it into the
microcuvettes-containing sample and incubating for 10 minutes at room
10

temperature. During incubation withdrawing and inserting the comb in the
microcuvettes for 15 seconds.
4. Removing the comb from the sample and blot the surface of the comb.
5. Washing the comb in the wash buffer solution for 10 times carefully by moving
the comb forward and back ward in the wash solution.
6. Immersing the comb in to the microcuvettes containing biotinylated HIV1 HIV2
antigen and p24 antibody and incubating for 10 minutes in room temperature.
Withdrawing and inserting the comb in to the microcuvettes for 15 seconds.
7. Washing the comb in the wash buffer solution for 10 minutes carefully by moving
the comb forward and backward in the wash solution.
8. Placing the comb in the microcuvettes containing Streptavidin Gold Conjugate
and incubating it for 10 minutes. Withdrawing and inserting the comb in the
solution for 15 seconds.
9. Taking the comb out and placing the comb on a clean surface, reactive side up
and allowing it to dry.
10. Reading the result only after the comb is completely dry.
According to the invention, a device for an early detection of the p24 antigen and
antibodies to HIV in the human beings, comprises of a polystyrene HIV comb having 8
teeth or comb, provided with three dots on each teeth or comb, the upper dot is an inbuilt
control dot, middle dot for the detection of p24 antigen and the lower dot for the
detection of HIV antibodies, wherein the dots for the detection of HIV is coated with
homogeneous solution of HIV antigen and control dot is coated with antihuman IgG and
the p24 detection dot is coated with monoclonal or polyclonal or (Fab!)2 p24 antibodies.
According to the present invention, A process for making the HIV Ag & Ab Comb
device for analyzing the presence of HIV antibodies and p24 antigen in human serum or
plasma comprises the following steps:
a. adding 5 mM - 100 mM carbonate buffer solution of pH 8- 9.6, 1 nano
gram to 10 micro To gram glycoprotein gp 41, C terminus of glycoprotein
120 and glycoprotein 36, vortexing the mixture to get a homogeneous
solution, coating 1 μl— 10 μl of the above mixture to the HIV 1 and HIV
11

2 detection dot and allow it to dry at 37°C for 1 hour to 20 hours and
preferably 4 hrs.
b. to 5 mM - 100 raM carbonate buffer solution of pH 8- 9.6, adding 1 nano
gram to 10 micro gram antihuman IgG for eg. of chicken or goat
vortexing the mixture to get a homogeneous solution, Coating 1 μl - 10
ul of the above mixture to the control dot and allowing it to dry at 37 ° C
for 1 hr to 20 hrs and preferably 4 hrs.
c. To 5 mM -100 mM carbonate buffer solution of pH 8- 9.6, adding 1 nano
gram to 10 micro gram specific monoclonal or polyclonal p24 antibodies
vortexing the mixture to get a homogeneous solution, Coating 1μl— 10
ul of the above mixture to the p24 antigen detection dot and allowing it to
dry at 37 ° C for 1 hr to 20 hrs and preferably 4 hrs .
According to the invention, a device as claimed in claim 1 wherein the device is adapted
to analyze as follows:-
a. taking 150 μl of sample in the microcuvettes and adding 150ul of sample diluent
to it.
b. mixing the sample with the sample diluent repeatedly avoiding formation of
bubbles while mixing the sample.
c. cutting the pouch and taking out the necessary no of combs and placing it into the
microcuvettes-containing sample and incubate for 10 minutes at room
temperature,
d. during incubation withdrawing and inserting the comb in the microcuvettes for 15
seconds.
e. removing the comb from the sample and blot the surface of the comb.
f. washing the comb in the wash buffer solution for 10 times carefully by moving
the comb forward and back ward in the wash solution.
g. placing the comb in the microcuvettes containing p24 conjugate and incubate it
for 10 minutes at room temperature.
h. withdrawing and inserting the comb in the wash buffer solution for 15 seconds
12

i. washing the comb in the wash buffer solution for 10 times carefully by moving
the comb forward and back ward in the wash solution.
j. immersing the comb in to the microcuvettes containing protein A conjugate and
incubate for 10 minutes in room temperature, withdrawing and inserting the comb
in to the microcuvettes containing protein A conjugate for 15 seconds.
k. Placing the comb on a clean surface, reactive side up and allow it to dry.
1. Reading the result only after the comb is completely dry.
The invention will be described with reference to the following accompanying drawings
wherein
Figure 1 shows the fourth generation of the HIV Ag/ Ab Comb.
This figure clearly shows the difference in the various devices developed from time to
time. In the first generation, the antibodies were detected only after 6 weeks. In the
second generation, the antibodies were detected before 6 weeks but after 4 weeks. In the
third generation, the antibodies were detected after three weeks but before 4 weeks. In the
fourth generation, the antigens were detected before three weeks but after 2 weeks. So
this is an important invention in the history of HIV.
Figure 2 shows the polystyrene comb.
Figure 3 shows the workability of the device is perfectly right.
Figure 4 shows the presence of HIV antibodies in the human serum or plasma and the
device is working properly.
Figure 5 shows the presence of p24 antigen in the human serum or plasma and the
workability of the device.
Figure 6 shows the presence of HIV antibodies and p24 antigen in the human serum or
plasma and the workability of the device.
Figure 7 shows the absence of HIV antigen and antibodies.
13

I Claim:-
1. A device for an early detection of the p24 antigen and antibodies to HIV in the
human beings, comprises of a polystyrene HIV comb having 8 teeth or comb,
provided with three dots on each teeth or comb, the upper dot is an inbuilt control dot,
middle dot for the detection of p24 antigen and the lower dot for the detection of HIV
antibodies, wherein the dots for the detection of HIV is coated with homogeneous
solution of HIV antigen and control dot is coated with antihuman IgG and the p24
detection dot is coated with monoclonal or polyclonal or (Fab')2 p24 antibodies.
2. A device as claimed in claim 1 wherein the dot for the detection of HIV 1 and
HIV 2 antibodies are coated with glycoprotein gp41, C terminus of gp 120 and gp
36 glycoprotein.
3. A device as claimed in claim 1 where in the antigens used for the coating are gp
41 , C terminus of gp 120 and gp 36.
4. A device as claimed in claim 1 wherein the control dot is coated with antihuman
IgG for example of rabbit, goat, donkey or chicken.
5. A device as claimed in claim 1 wherein the p24 detection dot is coated with
specific monoclonal or polyclonal or (Fab1)2 p 24 antibodies.
6. A device as claimed in claim 1 wherein 1 nano gram to 10 micro gram p24
antibodies are used for coating the p24 detection dot.
7. A process for making the HIV Ag & Ab Comb device for analyzing the presence
of HIV antibodies and p24 antigen in human serum or plasma comprises the
following steps:
a. adding 5 mM - 100 mM carbonate buffer solution of pH 8- 9.6, 1 nano
gram to 10 micro To gram glycoprotein gp 41, C terminus of glycoprotein
120 and glycoprotein 36, vortexing the mixture to get a homogeneous
solution, coating 1 ul - 10 ΜL of the above mixture to the HIV 1 and HIV
2 detection dot and allow it to dry at 37°C for 1 hour to 20 hours and
preferably 4 hrs.
b. to 5 mM - 100 mM carbonate buffer solution of pH 8- 9.6, adding 1 nano
gram to 10 micro gram antihuman IgG for eg. of chicken or goat
14

vortexing the mixture to get a homogeneous solution, Coating 1 μ1 — 10
μl of the above mixture to the control dot and allowing it to dry at 37 ° C
for 1 hr to 20 hrs and preferably 4 hrs.
c. To 5 mM -100 mM carbonate buffer solution of pH 8- 9.6, adding 1 nano
gram to 10 micro gram specific monoclonal or polyclonal p24 antibodies
vortexing the mixture to get a homogeneous solution, Coating 1 μ1 - 10
μ1 of the above mixture to the p24 antigen detection dot and allowing it to
dry at 37 ° C for 1 hr to 20 hrs and preferably 4 hrs .
8. A device as claimed in claim 1 wherein the device is adapted to analyze as
follows:-
a. taking 150 μl of sample in the microcuvettes and adding 150μl of sample
diluent to it.
b. mixing the sample with the sample diluent repeatedly avoiding formation
of bubbles while mixing the sample.
c. cutting the pouch and taking out the necessary no of combs and placing it
into the microcuvettes-containing sample and incubate for 10 minutes at
room temperature,
d. during incubation withdrawing and inserting the comb in the
microcuvettes for 15 seconds.
e. removing the comb from the sample and blot the surface of the comb.
f. washing the comb in the wash buffer solution for 10 times carefully by
moving the comb forward and back ward in the wash solution.
g. placing the comb in the microcuvettes containing p24 conjugate and
incubate it for 10 minutes at room temperature.
h. withdrawing and inserting the comb in the wash buffer solution for 15
seconds
i. washing the comb in the wash buffer solution for 10 times carefully by
moving the comb forward and back ward in the wash solution .
j. immersing the comb in to the microcuvettes containing protein A
conjugate and incubate for 10 minutes in room temperature, withdrawing
15

and inserting the comb in to the microcuvettes containing protein A
conjugate for 15 seconds.
k. Placing the comb on a clean surface, reactive side up and allow it to dry.
1. Reading the result only after the comb is completely dry.
9. A device for an early detection of the p24 antigen and antibodies to HIV in the
human beings substantially as hereinbefore described with reference to the
drawings.
10. A process for making the HIV Ag & Ab Comb device for analyzing the presence
of HIV antibodies and p24 antigen in human serum or plasma substantially as
hereinbefore described with reference to the drawings.
11. A device to analyze the p24 antigen & antibidoes to HIV substantially as
hereinbefore described with reference to the drawings.
Dated this 4th day of May, 2007.

16

The present invention HIV Ag & Ab Comb is a test device for the early detection of p24
antigen and HIV1 and HIV 2 antibodies in human serum or plasma or whole blood. It is
a visual, rapid, sensitive and accurate test kit for analyzing the presence of HIV
antibodies and p24 antigen in human serum or plasma or whole blood. In this test device,
the workability of the device can be tested simultaneously with the detection of the
presence of p24 antigen and antibodies to HIV.

Documents:

00693-kol-2007-abstract.pdf

00693-kol-2007-claims.pdf

00693-kol-2007-correspondence others 1.1.pdf

00693-kol-2007-correspondence others 1.2.pdf

00693-kol-2007-correspondence others.pdf

00693-kol-2007-correspondence.pdf

00693-kol-2007-description complete.pdf

00693-kol-2007-drawings.pdf

00693-kol-2007-form 1.pdf

00693-kol-2007-form 18.pdf

00693-kol-2007-form 2.pdf

00693-kol-2007-form 3.pdf

00693-kol-2007-form 5.pdf

00693-kol-2007-form 9 1.1.pdf

00693-kol-2007-form-9.pdf

00693-kol-2007-gpa.pdf

693-KOL-2007-ABSTRACT-1.1.pdf

693-KOL-2007-CLAIMS-1.1.pdf

693-KOL-2007-CORRESPONDENCE 1.3.pdf

693-KOL-2007-CORRESPONDENCE 1.4.pdf

693-KOL-2007-CORRESPONDENCE 1.5.pdf

693-KOL-2007-CORRESPONDENCE 1.6.pdf

693-KOL-2007-CORRESPONDENCE 1.7.pdf

693-KOL-2007-CORRESPONDENCE OTHERS.pdf

693-KOL-2007-CORRESPONDENCE-1.4.pdf

693-KOL-2007-CORRESPONDENCE-1.8.pdf

693-KOL-2007-FORM 1-1.1.pdf

693-KOL-2007-FORM 13-1.1.pdf

693-kol-2007-form 13-1.2.pdf

693-KOL-2007-FORM 13.1.3.pdf

693-kol-2007-form 13.pdf

693-KOL-2007-FORM 2-1.1.pdf

693-KOL-2007-FORM 26.pdf

693-KOL-2007-FORM 3-1.1.pdf

693-KOL-2007-FORM 5-1.1.pdf

693-KOL-2007-FORM-27.pdf

693-KOL-2007-OTHER DOCUMENT-1.2.pdf

693-KOL-2007-OTHERS-1.1.pdf

693-KOL-2007-PA.pdf

693-KOL-2007-PRE GRANT OPPOSITION-1.1.pdf

693-KOL-2007-PRE GRANT OPPOSITION.pdf

693-KOL-2007-REPLY TO EXAMINATION REPORT.pdf

693-KOL-2007-REPLY TO FIRST EXAMINATION REPORT.pdf


Patent Number 237854
Indian Patent Application Number 693/KOL/2007
PG Journal Number 04/2010
Publication Date 22-Jan-2010
Grant Date 11-Jan-2010
Date of Filing 07-May-2007
Name of Patentee MAHAJAN; LALIT
Applicant Address 1-D, MANHAR MAHAL, 4, BAKUL BAGAN ROA BEHIND LANSDOWNE MKT., KOLKATA - 700 025
Inventors:
# Inventor's Name Inventor's Address
1 MAHAJAN; LALIT 1-D, MANHAR MAHAL, 4, BAKUL BAGAN ROA BEHIND LANSDOWNE MKT., KOLKATA - 700 025
PCT International Classification Number C07K16/10
PCT International Application Number N/A
PCT International Filing date
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 NA